Contact Information
Department Information
Cardiology
Principal Investigator
Elizabeth Ofili, MD
Coordinator
JoAnn Cross, RN
Clinicaltrials.gov Details
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER HF)
Active
Purpose
The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared with placebo (inactive medication), in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and significant coronary artery disease following an episode of decompensated heart failure.
Start Date
August, 2014
End Date
December 2018
Investigator(s)
Elizabeth Ofili, MD
Interventions
Drug: Rivaroxaban
Drug: Placebo
Other: Standard of care of heart failure and coronary artery disease
Eligibility
Ages Eligible for Study: 18 years and older (Adult, Senior)
Sexes Eligible for Study: All
Accepts Healthy Volunteer: No